Rediscovery of insulin pump treatment of childhood type 1 diabetes

Minerva Medica

Volumn 95, Issue 2, 2004, Pages 85-92

  Weinzimer, S A ^a   Doyle, E A ^a   Steffen, A T ^a   Sikes, K A ^a   Tamborlane, W V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Child; Diabetes mellitus; Insulin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

BLOOD GLUCOSE MONITORING; CHILDHOOD DISEASE; CLINICAL TRIAL; DIABETIC MICROANGIOPATHY; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; PROGNOSIS; QUALITY OF LIFE; REVIEW; SOCIAL PSYCHOLOGY; WEIGHT GAIN;

BLOOD GLUCOSE SELF-MONITORING; CHILD; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 3042691469     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetics by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med 1979;300:573-8.
2. Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. BMJ 1978;1:204-7.
3. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983;24:326-9.
4. DCCT Research Group. The effects of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. N Engl J Med 1993;329:977-86.
5. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. J Pediatr 1994;125:177-88.
6. DCCT/EDIC Research Group. Prolonged beneficial effects of intensive therapy of diabetes during adolescence: microvascular outcomes four years after conclusion of the Diabetes Control and Complications Trial. J Pediatr 2001;139:804-12.
7. DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:1468-78.
8. Boland EA, Grey M, Fredrickson L, Tamborlane WV. CSII: a "new" way to achieve strict metabolic control, decrease severe hypoglycemia and enhance coping in adolescents with type I diabetes. Diabetes Care 1999;22: 1779-94.
9. Zinman B, Tildesley H, Chiasson TJ, Tsue E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-3.
10. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28),Pro(B29)]- human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402.
11. c levels across all age groups. Pediatr Diabetes 2002;3:10-15.
12. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001;107:351-6.
13. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003;26:1142-6.
14. Jones TW, Davis EA. Hypoglycemia in children with type 1 diabetes: current issues and controversies. Pediatr Diabetes 2003;4:143-50.
15. Chase HP, Saib SZ, MacKenzie T, Hansen MM, Garg SK. Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. Diabet Med 2002;19:317-21.
16. Kaufman FR, Kim C, Halvorson M, Pitukcheewanont P. Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. Diabetes Care 2000;23:579-82.
17. White NH, Hollander AS, Sadler M, Daniels L. Risks and benefits of continuous subcutaneous insulin infusion (CSII) therapy in children. Diabetes 2001;50 Suppl 2:A66.
18. Celona-Jacobs N, Weinzimer SA, Rearson M, Hartz D, Katz L, Murphy K. Insulin pump therapy in children: a cautionary tale. Diabetes 2001;50 Suppl 2:A67.
19. Laffei L, Loughlin C, Ramchandani N, Butler D, Laffei N, Levine B-S et al. Glycemic challenges of pump therapy (CSII) in youth with type 1 diabetes (T1DM). Diabetes 2001;50 Suppl 2:A66.
20. Tubiana-Rufi N, deLonlay P, Block J, Czernichow P. Remission of severe hypoglycemia incidents in young diabetic children treated with subcutaneous infusion. Arch Pediatr 1996;3:969-76.
21. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002; 141:490-5.
22. Weinzimer SA, Ahern JA, Boland EA, Steffen A, Tamborlane WV. Continuous subcutaneous insulin infusion (CSII) is safe and effective in very young children with type 1 diabetes mellitus (T1DM). Diabetes 2003; 52 Suppl 1:A402.
23. Sullivan-Bolyai S, Deatrick J, Gruppuso P, Tamborlane WV, Grey M. Constant vigilance: mothers' work parenting young children with type 1 diabetes. J Pediatr Nurs 2003;18:21-9.
24. Buckingham BA, Paguntalan H, Fassl B, Wilson DM. Continuous subcutaneous infusion (CSII) in children under five years of age. Diabetes 2001;50 Suppl 2:A107.
25. de Beaufort CE, Houtzagers CM, Bruining GJ, Aarsen RS, den Boer NC, Grose WF et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med 1989;6:766-71.
26. Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003;112:559-64.
27. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983;24:326-9.
28. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.
29. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K, Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15:369-76.
30. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26:799-804.
31. Boland EA, Weinzimer SA, Ahern JA, Steffen A, Tam-borlane WV. Randomized, prospective trial of CSII vs MDI with Glargine in children: a preliminary report. Diabetes 2003;52 Suppl 1:A45.
32. Ahern JA, Ramchandani N, Cooper J, Himmel A, Silver D, Tamborlane WV. Using a primary nurse manager to implement DCCT recommendations in a large pediatric program. Diabetes Educ 2000;26:990-4.
33. Matyka KA, Crowne EC, Havei PJ, Macdonald IA, Matthews D, Dunger DB. Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. Diabetes Care 1999;22: 1144-50.
34. Boland EA, Monsod T, DeLucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self monitoring of blood glucose: lessons learned from three days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24:1858-62.
35. Mastrototaro J. The MiniMed Continuous Glucose Monitoring System (CGMS). J Pediatr Endocrinol Metab 1999;12 Suppl 3:751-8.
36. Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA 1999;282:1839-44.
37. Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R et al. Continuous subcutaneous monitoring in children with type 1 diabetes. Pediatrics 2001;107:222-6.
38. Kaufman FR, Austin J, Neinstein A, Jeng L, Halvorson M, Devoe DJ et al. Nocturnal hypoglycemia detected with the Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes. J Pediatr 2002;141:625-30.
39. Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the CGMS in children with type 1 diabetes: results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther 2003;5:781-9.
40. Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the GlucoWatch G2 biographer in children with type 1 diabetes: results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther 2003;5:791-800.
41. Diabetes Research in Children Network (DirecNet) Study Group. A multicenter study of the accuracy of the One Touch Ultra home glucose meter in children with type 1 diabetes. Diabetes Technol Ther 2003;5:933-41.
42. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W et al. Clinical control of diabetes by the artificial pancreas. Diabetes 1974;23:397-404.